Acceleron Pharma Inc. (NASDAQ:XLRN) Director Jean George sold 105,122 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the transaction, the director now owns 1,250 shares in the company, valued at approximately $44,662.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Acceleron Pharma Inc. (NASDAQ:XLRN) traded down $0.08 during midday trading on Monday, hitting $35.92. 1,100,600 shares of the company traded hands, compared to its average volume of 384,954. Acceleron Pharma Inc. has a twelve month low of $23.07 and a twelve month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. During the same quarter last year, the business posted ($0.55) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. analysts forecast that Acceleron Pharma Inc. will post -2.65 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the stock. Oppenheimer restated a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. HC Wainwright reiterated a “buy” rating and set a $62.00 price target on shares of Acceleron Pharma in a research report on Monday, December 11th. Credit Suisse Group set a $51.00 price target on shares of Acceleron Pharma and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Royal Bank of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Finally, ValuEngine lowered shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $44.56.

A number of institutional investors have recently modified their holdings of XLRN. Perceptive Advisors LLC boosted its position in Acceleron Pharma by 127.2% in the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after acquiring an additional 534,440 shares during the last quarter. Sectoral Asset Management Inc raised its stake in shares of Acceleron Pharma by 378.2% during the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after acquiring an additional 478,099 shares during the last quarter. BlackRock Inc. raised its stake in shares of Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after acquiring an additional 330,635 shares during the last quarter. Finally, AXA bought a new position in shares of Acceleron Pharma during the second quarter valued at $9,833,000. Hedge funds and other institutional investors own 85.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Acceleron Pharma Inc. (XLRN) Director Jean George Sells 105,122 Shares” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/18/acceleron-pharma-inc-xlrn-director-jean-george-sells-105122-shares.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.